Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors.
作者： Dan Wang , Li Yang , Weina Yu , Yi Zhang
DOI: 10.1080/13543784.2019.1672655
关键词: Cancer research 、 Cancer 、 Receptor tyrosine kinase 、 Tyrosine kinase 、 Fibroblast growth factor receptor 2 、 Clinical trial 、 Combination therapy 、 Monoclonal antibody 、 Tumor progression 、 Medicine
摘要: Introduction: Fibroblast growth factor receptor 2 (FGFR2) is a highly conserved transmembrane tyrosine kinase receptor. FGFR2 dysregulation occurs in numerous human solid tumors and overexpression closely associated with tumor progression. has recently been reported as therapeutic target for cancer. Several targeted therapies are being investigated to disrupt activity; these include multi-target inhibitors (TKIs), pan-FGFR TKIs monoclonal antibodies. Areas: This review examines regulation function cancer its potential treatment. Expert opinion: Highly specific blockers have not yet developed moreover, resistance FGFR2-targeted challenge. More sophisticated patient selection strategies would help improve combination therapy considered the most promising approach patients alterations.
sci-hub.se 参考文章(160)
Siew-Ging Gong, Isoforms of Receptors of Fibroblast Growth Factors Journal of Cellular Physiology. ,vol. 229, pp. 1887- 1895 ,(2014) , 10.1002/JCP.24649
Helen Künstlinger, Jana Fassunke, Hans-Ulrich Schildhaus, Benedikt Brors, Carina Heydt, Michaela Angelika Ihle, Gunhild Mechtersheimer, Eva Wardelmann, Reinhard Büttner, Sabine Merkelbach-Bruse, FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro Oncotarget. ,vol. 6, pp. 20215- 20230 ,(2015) , 10.18632/ONCOTARGET.4046
Sara A Byron, Huaibin Chen, Andreas Wortmann, David Loch, Michael G Gartside, Farhad Dehkhoda, Steven P Blais, Thomas A Neubert, Moosa Mohammadi, Pamela M Pollock, The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia. ,vol. 15, pp. 975- 988 ,(2013) , 10.1593/NEO.121106
Yanqing Huang, Tomoaki Hamana, Junchen Liu, Cong Wang, Lei An, Pan You, Julia Y. F. Chang, Jianming Xu, Chengliu Jin, Zhongying Zhang, Wallace L. McKeehan, Fen Wang, Type 2 Fibroblast Growth Factor Receptor Signaling Preserves Stemness and Prevents Differentiation of Prostate Stem Cells from the Basal Compartment Journal of Biological Chemistry. ,vol. 290, pp. 17753- 17761 ,(2015) , 10.1074/JBC.M115.661066
Gottfried E Konecny, Neil Finkler, Agustin A Garcia, Domenica Lorusso, Paula S Lee, Rodney P Rocconi, Peter C Fong, Matt Squires, Kaushal Mishra, Allison Upalawanna, Yongyu Wang, Rebecca Kristeleit, Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Lancet Oncology. ,vol. 16, pp. 686- 694 ,(2015) , 10.1016/S1470-2045(15)70159-2
Yasmine Tanner, Richard P. Grose, Dysregulated FGF signalling in neoplastic disorders Seminars in Cell & Developmental Biology. ,vol. 53, pp. 126- 135 ,(2016) , 10.1016/J.SEMCDB.2015.10.012
Masaru Katoh, Hitoshi Nakagama, FGF receptors: cancer biology and therapeutics. Medicinal Research Reviews. ,vol. 34, pp. 280- 300 ,(2014) , 10.1002/MED.21288
G Yan, Y Fukabori, G McBride, S Nikolaropolous, W L McKeehan, Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Molecular and Cellular Biology. ,vol. 13, pp. 4513- 4522 ,(1993) , 10.1128/MCB.13.8.4513
Teresa Helsten, Sheryl Elkin, Elisa Arthur, Brett N. Tomson, Jennifer Carter, Razelle Kurzrock, The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing Clinical Cancer Research. ,vol. 22, pp. 259- 267 ,(2016) , 10.1158/1078-0432.CCR-14-3212
RYUJI OHASHI, YOKO MATSUDA, TOSHIYUKI ISHIWATA, ZENYA NAITO, Downregulation of fibroblast growth factor receptor 2 and its isoforms correlates with a high proliferation rate and poor prognosis in high-grade glioma. Oncology Reports. ,vol. 32, pp. 1163- 1169 ,(2014) , 10.3892/OR.2014.3283